Clinical Indications for Effects of Methotrexate in Rheumatiod Arthritis.

概要

論文の詳細を見る
We experienced methrtrexate (MTX) therapy at a low dose level of 1, 25-7.5mg/week in 10 refractory RA patients with an uncontrollable inflammatory process, and studied its indication and effects. Eight of these 10 patievds began to show an improved Lansbury index value about 4 weeks after the initiation of drug therapy. Among the components of the Lansbury index a definite improvement was noted in morning stiffness, srasping power and the joint score, while the erythrocyte sedimentation rata improved slightly. No efficacy side effects occsred in one of 10 patients with the elevation of the transaminase serum level. The results of this therapeutic trial with MTX indicate that a favorable response can be expected even at a low dose level of 2.5mg/week or below in those patients with refractory RA whose treatment by gold sodium thrimalate, auranofin, bucllamine, D-penicillamine and or steroids has not been effective.